FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to oncology, and concerns treatment of androgen-receptor-positive breast cancer. To this end an effective amount of selective androgen receptor modulator (SARM) is administered.
EFFECT: it provides effective treatment of breast cancer, including such forms as metastatic, refractory, AR-positive, due to AR-mediated tissue selective activity of these compounds.
32 cl, 17 ex, 16 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING ANDROGEN RECEPTOR (AR)-POSITIVE FORMS OF BREAST CANCER USING SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM) | 2013 |
|
RU2717835C2 |
| COMPOSITIONS AND METHODS OF TREATING ANDROGEN-RECEPTOR-POSITIVE CANCER | 2020 |
|
RU2817802C2 |
| METHODS OF TREATING AR+ BREAST CANCER | 2017 |
|
RU2769527C2 |
| SELECTIVE ANDROGEN RECEPTOR DESTROYING AGENTS (SARD) AND METHODS OF USING THEREOF | 2016 |
|
RU2724103C2 |
| ANDROGEN RECEPTOR SELECTIVE DESTROYING (SARD) LIGANDS AND METHODS OF THEIR USE | 2017 |
|
RU2795431C2 |
| SELECTIVE ANDROGEN RECEPTOR DESTROYING (SARD) LIGANDS AND METHODS OF USING THEM | 2016 |
|
RU2689988C2 |
| MODULATION OF ANDROGEN RECEPTOR EXPRESSION | 2013 |
|
RU2670486C9 |
| TREATING THREE RECEPTOR NEGATIVE BREAST CANCER | 2007 |
|
RU2448697C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
